Abstract
A simple procedure has been elaborated to screen for the calmodulin antagonist effect of drugs. A covalently attached fluorescent probe was used to monitor the binding of enzymes known as target enzymes to calmodulin. Moreover, the probe made it possible to recognize a new target enzyme, aldolase (D-fructose-1,6-bisphosphate D-glyceraldehyde-3-phosphate-lyase, EC 4.1.2.13), for calmodulin among glycolytic enzymes. The calmodulin antagonist trifluoperazine prevented or eliminated the complex formation between calmodulin and enzymes studied in reconstituted systems; the Ca channel blockers had no effect. The functional consequences of the effect of drugs on calmodulin-phosphofructokinase (ATP:D-fructose-6-phosphate 1-phosphotransferase, EC 2.7.1.11) interaction were investigated as well. Whereas trifluoperazine suspended the calmodulin-mediated hysteretic inactivation of phosphofructokinase, Ca channel blockers (verapamil and nifedipine) were ineffective. Fendiline (regarded as a Ca channel blocker) seems to act as a functional calmodulin antagonist. Its binding to calmodulin does not prevent the complex formation of phosphofructokinase and calmodulin, but within this ternary complex phosphofructokinase preserves or recovers its original activity measured in the absence of calmodulin. The possible molecular effect of drugs on a calmodulin-enzyme complex is discussed.
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|